Jam

Seer and Korea University are collaborating on a large-scale study to discover early cancer biomarkers using Seer’s Proteograph ONE Assay and mass spectrometry. This initiative aims to analyze 20,000 plasma samples to identify novel blood-based biomarkers for improved cancer diagnostics, particularly for young adults. The study, supported by the K-Health MIRAE initiative, utilizes AI-driven analytics, promising accelerated analysis, reduced costs, and the potential for earlier cancer detection and improved patient outcomes.

NIO Inc. reported strong May 2025 delivery figures. May deliveries reached 23,231 vehicles, a 13.1% year-over-year increase. Year-to-date deliveries totaled 89,225, up 34.7% year-over-year. Cumulative deliveries reached 760,789 vehicles by the end of May, reflecting growth across its NIO, ONVO, and FIREFLY brands. The company’s strategic expansion targets diverse segments.

Innovent Biologics announced positive Phase 1/2 data for IBI363, a PD-1/IL-2α-bias bispecific antibody, at ASCO 2025. The study showed promising results in immunotherapy-resistant acral and mucosal melanoma (“cold tumors”), demonstrating a 23.3% confirmed objective response rate and 14.8 months median overall survival. A Phase 2 registration trial for IBI363 is underway, offering a potential breakthrough for advanced melanoma treatment.

PetroFrontier Corp. (TSXV: PFC) announces further delays in filing financial statements. Annual filings are now expected by June 26, 2025 and Q1 filings by July 10, 2025, impacting CEO/CFO trading and an existing cease trade order. The company cites data delays from its limited partnership investment. While providing biweekly updates, PetroFrontier, focused on Alberta heavy oil plays, faces exchange listing risks related to these delays.

Actuate Therapeutics announced positive Phase 2 results for elraglusib in previously untreated metastatic pancreatic cancer. The combination with gemcitabine/nab-paclitaxel significantly improved overall survival to 10.1 months, compared to 7.2 months for the control, with a 37% reduction in death risk. The 12-month survival rate also doubled. Actuate plans to discuss product registration with the FDA.

A Phase 3 trial (PANOVA-3) showed that Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel improved overall survival in patients with unresectable, locally advanced pancreatic cancer and reduced pain duration compared to chemotherapy alone. The results are published in the *Journal of Clinical Oncology* and will be presented at ASCO. Novocure plans to submit the data to the FDA for approval.

Tempus AI launched its Fuses program to create an AI-powered diagnostic platform for precision medicine. Leveraging its vast, multimodal dataset, the initiative will build models to improve diagnostics, prognostics, and predictions. Fuses aims to translate data insights into clinically validated tests for personalized patient care, including identifying those unlikely to respond to current therapies. The program seeks to transform diagnostics and help match patients with the most effective treatments.

Genentech announced positive overall survival data from the Phase III INAVO120 study, showing that the Itovebi regimen reduced death risk by over 30% in advanced breast cancer patients with PIK3CA mutations. Compared to palbociclib and fulvestrant alone, this Itovebi combination with palbociclib and fulvestrant significantly improved overall survival. The findings will be presented at the 2025 ASCO meeting.

Destination XL Group (DXLG) opened a new DXL store in Boca Raton, Florida, its fifth new store this fiscal year. Catering to Big + Tall menswear, the store offers exclusive designs and various brands. DXL utilizes FiTMAP^SM Sizing Technology for personalized recommendations. This expansion aims to provide a streamlined shopping experience and empower customers to express their personal style through well-fitting apparel.

Gold Reserve Ltd. announced a deadline extension in the Citgo Petroleum sale linked to Venezuela. The U.S. District Court granted the Venezuelan parties more time to submit bids for PDVH, Citgo’s holding company, with a new “Topping Period” deadline of June 18, 2025. Key dates for legal proceedings were also outlined, including a final recommendation by June 27, 2025, and a sale hearing on July 22, 2025. Gold Reserve anticipates bidding but acknowledges the deal faces significant risks, including potential regulatory challenges.